Annual Meeting: March 19 – 23, 2023
ToxExpo: March 20 – 22, 2023

Nashville Music City Center, Nashville, TN

Exhibitor Service Center

Lhasa Limited

Leeds,  West yorkshire 
United Kingdom
  • Booth: 403

Supporting informed decision making on chemical safety

At Lhasa, we are driven by our purpose; To enable informed decision making on chemical safety. In line with this purpose, we create forward-thinking software solutions, which solve real-world chemical safety assessment problems. Our technology is designed by scientists, for scientists, in collaboration with industry stakeholders and regulators. Our exhibitor hosted sessions discuss tackling ICH S1B using AOPs and using in silico tools to support drug development.

 Press Releases

  • Lhasa Limited is thrilled to announce the launch of Kaptis!

    Aligned with the recent finalisation of the ICH S1B(R1) guideline, Kaptis includes ICH S1 functionality. The ICH S1 functionality supports more efficient evaluation of compound carcinogenic potential and can be used to determine whether a full carcinogenicity animal study is necessary.

    Lhasa has invested a significant amount of time into understanding this area, earlier this year forming an ICH S1 consortium. The consortium consists of several key industry partners, all with a common goal of supporting meeting ICH S1 in a faster and more cost-effective manner.

    This launch of Kaptis means that for the first time, scientists around the world can use adverse outcome pathway (AOP) networks to perform carcinogenicity assessments, utilising transparent AOP knowledge developed by Lhasa, alongside proprietary assay data.

    Kaptis can be used to answer the question, “Is my compound likely to be carcinogenic?”, with Kaptis ICH S1 reporting also designed to support consistent industry carcinogenicity assessments and ICH S1 regulatory submission.

    "Kaptis is an important tool for the development and interpretation of Integrated Approaches to Testing and Assessment for carcinogenicity" – Carole Yauk, Professor and Canada Research Chair in Genomics and the Environment.

    Ultimately the uptake of Kaptis will result in more transparent, faster and cheaper carcinogenicity assessments which also minimise the use of animal testing – resulting in more ethical and environmentally friendly assessments.

    If you would like to learn more about how this innovative solution would improve your own ICH S1 carcinogenicity assessments, please get in touch or email us at

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".